📰 Definitive Proxy Statement News
Page 35 - Definitive Proxy Statement News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Definitive Proxy Statement. Real-time updates on events, politics, business and more.
December 13, 2022
/PRNewswire/ -- Berenson Acquisition Corp. I (NYSE: BACA) (the "Company") today announced that the special meeting of stockholders of the Company (the "Special...
December 12, 2022
/PRNewswire/ -- Venus Acquisition Corporation (the "Company" or "Venus") (NASDAQ: VENA) today announced that, on December 9, 2022, the Company closed the...
December 12, 2022
NEW YORK, Dec. 13, 2022 /PRNewswire/ -- Venus Acquisition Corporation (the "Company" or "Venus") (NASDAQ: VENA) today announced that, on December 9, 2022, the Company closed the previously announced business combination (the "Business Combination") with VIYI Algorithm Inc. (the "VIYI") pursuant to which the Venus Merger Sub ("Venus Merger Sub"), a Cayman Islands exempted company incorporated for the purpose...
December 7, 2022
/PRNewswire/ -- D and Z Media Acquisition Corp. (NYSE: DNZ) (the "Company") today announced that the special meeting in lieu of the 2022 annual meeting of...
December 7, 2022
ATLANTA, Dec. 7, 2022 /PRNewswire/ -- D and Z Media Acquisition Corp. today announced that the special meeting in lieu of the 2022 annual meeting of stockholders of the Company , originally...
December 7, 2022
/PRNewswire/ -- D and Z Media Acquisition Corp. (NYSE: DNZ) (the "Company") today announced that the special meeting in lieu of the 2022 annual meeting of...
December 6, 2022
Equillium grants Ono an option to purchase rights to itolizumabEquillium to receive an upfront payment of approximately $26.0M (¥3.5B); eligible to receive up to approximately $138.5M (¥18.7B) in option exercise and milestone paymentsOno to fund Equillium’s continued research and development of itolizumab during the...
December 6, 2022
Seeks to Avoid Delisting from Nasdaq Capital Market...
November 21, 2022
INFINT Acquisition Corporation , announced today that it affirmed its intention to support the proposal to amend the Company’s Amended and Restated Memorandum and Articles of Association to... | November 21, 2022
November 15, 2022
SEATTLE, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Kineta, Inc. (“Kineta” or the “Company”), a clinical-stage biotechnology company focused on developing...